(2)
First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation
Data from ongoing phase 1 COVID-19 study show that MP0420 (ensovibep) is well tolerated in first dose cohort
Unique immunomodulation platforms advanced to readiness for candidate generation using CD-3 T cell engagers and pMHC binders
Virology portfolio launched with focus on major global viral threats where unique DARPin® therapeutic profile could make major impact
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / December 17, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced multiple advances across clinical and preclinical programs, as well as an expansion of its corporate strategy to develop a portfolio of therapies targeting global viral threats. These advances will be de
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments – – Agreement includes royalties of up to 20 percent on net sales payable to Aurinia – Aurinia Pharmaceuticals Inc. today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral … – Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments –